Lifecore Biomedical (NASDAQ:LFCR) Upgraded at Barrington Research

Barrington Research upgraded shares of Lifecore Biomedical (NASDAQ:LFCR) from a market perform rating to an outperform rating in a research report released on Tuesday, Marketbeat.com reports. Barrington Research currently has $5.50 price target on the stock.

Several other research analysts also recently issued reports on the company. Zacks Research raised Lifecore Biomedical to a “hold” rating in a research note on Thursday, January 1st. Weiss Ratings reissued a “sell (d)” rating on shares of Lifecore Biomedical in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $5.50.

Lifecore Biomedical Trading Down 2.2%

Shares of LFCR stock opened at $4.06 on Tuesday. Lifecore Biomedical has a twelve month low of $3.98 and a twelve month high of $8.98. The stock’s fifty day simple moving average is $7.32 and its 200 day simple moving average is $7.42. The company has a quick ratio of 1.67, a current ratio of 2.80 and a debt-to-equity ratio of 113.76. The firm has a market capitalization of $152.17 million, a P/E ratio of -4.14 and a beta of 0.62.

Lifecore Biomedical (NASDAQ:LFCR) last posted its earnings results on Monday, March 16th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.05). Lifecore Biomedical had a negative net margin of 23.08% and a negative return on equity of 1,211.09%. The firm had revenue of $35.75 million during the quarter, compared to the consensus estimate of $35.31 million. As a group, sell-side analysts predict that Lifecore Biomedical will post -0.91 EPS for the current fiscal year.

Hedge Funds Weigh In On Lifecore Biomedical

Hedge funds have recently made changes to their positions in the stock. Grizzlyrock Capital LLC bought a new stake in Lifecore Biomedical in the second quarter valued at approximately $5,964,000. Invesco Ltd. bought a new position in Lifecore Biomedical during the 2nd quarter worth approximately $3,081,000. Squarepoint Ops LLC lifted its position in shares of Lifecore Biomedical by 385.9% in the 3rd quarter. Squarepoint Ops LLC now owns 150,909 shares of the company’s stock worth $1,111,000 after purchasing an additional 119,851 shares during the period. Millennium Management LLC lifted its position in shares of Lifecore Biomedical by 86.2% in the 4th quarter. Millennium Management LLC now owns 251,705 shares of the company’s stock worth $2,059,000 after purchasing an additional 116,500 shares during the period. Finally, Greenhaven Road Investment Management L.P. boosted its stake in shares of Lifecore Biomedical by 2.2% in the 2nd quarter. Greenhaven Road Investment Management L.P. now owns 3,694,832 shares of the company’s stock valued at $30,002,000 after purchasing an additional 78,686 shares during the last quarter. 83.36% of the stock is currently owned by institutional investors.

About Lifecore Biomedical

Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.

The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.